SureTrader Advertisement Advertisement Advertisement
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Mocha Jet, Drugdoctor, RizZo, lasers, John_Langston, IB_
Search This Board:
Last Post: 10/6/2015 12:05:01 PM - Followers: 677 - Board type: Free - Posts Today: 16

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

Apr 21, 2015
Elite Pharmaceuticals Announces Launch Of Generic Hydroxyzine Tablets

Feb 17, 2015
Elite Pharmaceuticals Provides Guidance On Phase III Study For ELI-200

Jan, 15 2015
Elite Pharmaceuticals Announces First Shipment Of Generic Isradipine Capsules

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:

Third Quarter ending December 31, 2014
♦  Consolidated revenues for the third quarter of Fiscal 2015 continued their upward trend, rising to $1.4 million, an increase of approximately 8.5% over consolidated revenues for the second quarter of Fiscal 2015. The third quarter revenues for this year were $0.3 million below revenues reported for the third quarter of the prior fiscal year due to a one-time $0.6 million milestone that occurred in the prior year third quarter. Development of our proprietary abuse-deterrent opioid technology continues to be Elite's top priority. During the quarter, Elite invested an additional $2.3 million in clinical trials and other product development activities.

Highlights for the third quarter
♦  As of December 31, our working capital was $8.9 million, including cash of $8.3 million.
♦  Isradipine was recently launched, and we expect to introduce Hydroxyzine and Dantrolene in the near-term.
♦  We're a penny stock company with eyes on NASDAQ; we need to be Sarbanes Oxley compliant. So we are evaluating the gaps that we have by hiring consultants and external consultants in order to evaluate the checks and      balances we have in order for us to get there.
♦  We are creating infrastructure in our facilities with expanding the facilities and adding new equipment and upgrading the current equipment in order to support our (Eli-200) product launch.
2014 was our best year, 2015 will be the year we file our first ART product, and Q1 2016 will be the year we launch our first ART product and hopefully will be the year we will be on NASDAQ.

Nine-Month Period Ending December 31, 2014
♦  Revenues for the nine months ending December 31, 2014 were $3.8 million, an increase of 6% over revenues for the comparable period of the prior year, even with the one-time milestone being included in the prior year revenues. The increase in revenues is due to the continued growth and expansion of Elite's generic product lines.
♦  During the first nine months of the fiscal year, Elite has invested a total of $9.9 million in product development, including successful completion of the human abuse liability study for ELI-200.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


                                             ELTP Potential Share Price in Relation to Percentage of Pain Market Captured

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Statement of Changes in Beneficial Ownership (4) 08/18/2015 02:43:08 PM
ELTP News: Quarterly Report (10-q) 08/10/2015 04:27:45 PM
ELTP News: Amended Statement of Beneficial Ownership (sc 13d/a) 07/16/2015 04:52:46 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 06/22/2015 02:47:10 PM
ELTP News: Annual Report (10-k) 06/15/2015 04:36:59 PM
#166111  Sticky Note Given the timeframe under which the Epic Elite Couch 09/30/15 01:48:42 PM
#162745  Sticky Note TO THE NEWBIES INTERESTED IN BUYING THIS STOCK: Couch 08/18/15 03:37:57 PM
#160893  Sticky Note We've launched, what - 8 products... since you Dr Speculator Ninja 08/01/15 12:20:57 PM
#156597  Sticky Note A few more additional FACTS about the Actavis/Epic/Elite Couch 06/11/15 08:13:37 PM
#148487  Sticky Note Ya-don't-say???-Trial-record-1 of-66-for:-eli-200 Drugdoctor 03/21/15 11:04:27 AM
#106205  Sticky Note Elite’s 1st Generation Triple Patents and their Purpose lasers 04/30/14 08:50:54 AM
#166429   I heard the same misinformation/bs since the .06's. Couch 10/06/15 12:05:01 PM
#166427   I don't recommend anyone buy or not buy. richme 10/06/15 11:58:00 AM
#166425   Hey, Cheers! Aqua 10/06/15 11:28:26 AM
#166422   We got an estimated time on release of goodh2o1 10/06/15 10:54:29 AM
#166421[ NASDAQ2020 10/06/15 10:53:39 AM
#166420   I apologize! I guess there are cases of richme 10/06/15 10:30:11 AM
#166419   Does Elite the company make ELTP the stock mrwrn2010 10/06/15 10:20:11 AM
#166418   I take exception to your pronouncement that no no2koolaid 10/06/15 10:13:52 AM
#166417   Im upset I only have 500% gains, too. NASDAQ2020 10/06/15 10:03:50 AM
#166416   Where is the link to refute the potential no2koolaid 10/06/15 09:54:33 AM
#166414   DRUG COST SURGE SCHH 10/06/15 09:31:04 AM
#166411   That table was created by AJ. Maybe he YJ4LIFE 10/05/15 09:55:06 PM
#166410   Bngo, That table has been posted for some time Mocha Jet 10/05/15 09:51:35 PM
#166408   ELTP is perfect. Couch 10/05/15 09:00:26 PM
#166407   Clearly Nasrat can't cash out until either he Couch 10/05/15 08:47:59 PM
#166406   It's not a question of if $2 - Couch 10/05/15 08:43:44 PM
#166405   Actually Nasrat said he would be dropping the Couch 10/05/15 08:35:55 PM
#166404   Moderator, Please sticky note / push pin, etc. this Bngo 10/05/15 08:32:18 PM
#166403   Interest in ELTP noted. NASDAQ2020 10/05/15 07:51:16 PM
#166402   Shorts seem on edge with PH III results imminent. NASDAQ2020 10/05/15 07:43:40 PM
#166401   Your right! NASDAQ2020 10/05/15 07:39:44 PM
#166399   ELTP is awesome but I am out; good night. John_Langston 10/05/15 07:10:04 PM
#166398   I'm a newbie here on the board and John_Langston 10/05/15 07:02:23 PM
#166397   Throw ELI-216(24hr ADF oxy)on the heap. John_Langston 10/05/15 06:58:11 PM
#166396   When I dream I dream BIG. LOL John_Langston 10/05/15 06:55:22 PM
#166395   1) 2/ 3 ADT opioids on the market John_Langston 10/05/15 06:53:28 PM
#166394   Buyers paying for 17 ADFs in advance. John_Langston 10/05/15 06:48:15 PM
#166393   Depends how long you hold. GL John_Langston 10/05/15 06:46:07 PM
#166391   Please explain how Nasrat cashes out on his John_Langston 10/05/15 06:42:49 PM
#166390   no use in discussing something that will not happen! John_Langston 10/05/15 06:41:20 PM
#166389   The 5 year deal with Epic would suggest John_Langston 10/05/15 06:39:27 PM
#166387   $8.00 PPS buyout will never happen John_Langston 10/05/15 06:36:02 PM
#166386   One so called expert said that naloxone only John_Langston 10/05/15 06:34:29 PM
#166385   Phase 3 positive data dropping any day now. John_Langston 10/05/15 06:30:28 PM
#166384   Clearly Nasrat has a PPS in mind in Couch 10/05/15 06:24:51 PM
#166383   That is without a split. With a 3/1 Couch 10/05/15 06:04:23 PM
#166382   Time from $0.04 in 2011 we'll spend. NASDAQ2020 10/05/15 06:03:12 PM
#166381   Certainly didn't dispute it eh? Lol mrwrn2010 10/05/15 05:33:03 PM
#166379   I'm a newbie here on the board and Anaja 10/05/15 04:44:46 PM
#166378   Heard quite a few "never"s about ELTP since mrwrn2010 10/05/15 04:43:54 PM
#166377   Spot on Mocha Jet.. And btw thank you.. Gman24 10/05/15 04:43:17 PM
#166376   It will be 4X after 2-3 adt opiods; NASDAQ2020 10/05/15 04:36:40 PM
#166375   But it only sticks when a healthy growing NASDAQ2020 10/05/15 04:34:18 PM
#166374   Except I never claimed that lol dr_lowenstein 10/05/15 04:33:20 PM
#166373   Ans all that without a shred of factual support. Mocha Jet 10/05/15 04:30:05 PM
#166372   Throw ELI-216(24hr ADF oxy)on the heap. NASDAQ2020 10/05/15 04:26:39 PM
#166370   LOL this keeps getting better and better. Now dr_lowenstein 10/05/15 04:17:01 PM
#166369   Well, the logic seems so obviously consistent with no2koolaid 10/05/15 04:05:32 PM
#166368   Agree with all but the number 2 would mightymk 10/05/15 04:04:55 PM
#166367   One of the difficulties in trying to figure no2koolaid 10/05/15 04:01:09 PM